Everolimus: an immunosuppressive agent in transplantation

Bibliography

• KEOGH A, RICHARDSON M, RUYGROK P et al.: Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation (2004) 110:2694-2700.
   PubMed Web of Science ®Google Scholar
• EISEN HJ, TUZCU EM, DORENT R et al.: Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. (2003) 349:847-858.
   PubMed Web of Science ®Google Scholar
• KAUFFMAN HM, CHERIKH WS, CHENG Y, HANTO DW, KAHAN BD: Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation (2005) 80:883-889.
   PubMed Web of Science ®Google Scholar
• PIRSCH JD, MILLER J, DEIERHOI MH, VINCENTI F, FILO RS: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation (1997) 63:977-983.
   PubMed Web of Science ®Google Scholar
• MENTZER RM Jr, JAHANIA MS, LASLEY RD: Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The US Multicenter FK506 Study Group. Transplantation (1998) 65:109-113.
   PubMed Web of Science ®Google Scholar
• ONSAGER DR, CANVER CC, JAHANIA MS et al.: Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J. Heart Lung Transplant. (1999) 18:448-455.
   PubMed Web of Science ®Google Scholar
• FELLDIN M, BACKMAN L, BRATTSTROM C et al.: Rescue therapy with tacrolimus (FK 506) in renal transplant recipients-a Scandinavian multicenter analysis. Transpl. Int. (1997) 10:13-18.
   PubMed Web of Science ®Google Scholar
• KOBASHIGAWA JA, PATEL J, FURUKAWA H et al.: Five-year results of a randomized, single-center study of tacrolimus versus microemulsion cyclosporine in heart transplant patients. J. Heart Lung Transplant. (2006) 25:434-439.
   PubMed Web of Science ®Google Scholar
• KOBASHIGAWA J, MILLER L, RENLUND D et al.: A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation (1998) 66:507-515.
   PubMed Web of Science ®Google Scholar
• WIESNER R, RABKIN J, KLINTMALM G et al.: A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl. (2001) 7:442-450.
   PubMed Web of Science ®Google Scholar
• LAMA R, SANTOS F, ALGAR FJ, ALVAREZ A, BAAMONDE C: Lung transplants with tacrolimus and mycophenolate mofetil: a review. Transplant. Proc. (2003) 35:1968-1973.
   PubMed Web of Science ®Google Scholar
• SOLLINGER HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation (1995) 60:225-232.
   PubMed Web of Science ®Google Scholar
• A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation (1996) 61:1029-1037.
   PubMed Web of Science ®Google Scholar
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet (1995) 345:1321-1325.
   PubMed Web of Science ®Google Scholar
• PATEL JK, KOBASHIGAWA J: Allograft coronary artery disease. In: Advanced Therapy in Cardiac Surgery, 2nd edn. Franco KL, Verrier ED (Eds) BC Decker, Inc., Hamilton (2002):580-592.
   Google Scholar
• RADOVANCEVIC B, VRTOVEC B: Sirolimus therapy in cardiac transplantation. Transplant. Proc. (2003) 35:71S-176S.
   Google Scholar
• KAHAN BD: Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet (2000) 356:194-202.
   PubMed Web of Science ®Google Scholar
• MACDONALD AS: A worldwide, Phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation (2001) 71:271-280.
   PubMed Web of Science ®Google Scholar
• SCHULER W, SEDRANI R, COTTENS S et al.: SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation (1997) 64:36-42.
   PubMed Web of Science ®Google Scholar
• SCHUURMAN HJ, COTTENS S, FUCHS S et al.: SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation (1997) 64:32-35.
   PubMed Web of Science ®Google Scholar
• COLE OJ, SHEHATA M, RIGG KM: Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant. Proc. (1998) 30:2200-2203.
   PubMed Web of Science ®Google Scholar
• SCHUURMAN HJ, PALLY C, WECKBECKER G, SCHULER W, BRUNS C: SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant. Proc. (1999) 31:1024-1025.
   PubMed Web of Science ®Google Scholar
• FARB A, JOHN M, ACAMPADO E, KOLODGIE FD, PRESCOTT MF, VIRMANI R: Oral everolimus inhibits in-stent neointimal growth. Circulation (2002) 106:2379-2384.
   PubMed Web of Science ®Google Scholar
• MATSUMOTO Y, HOF A, BAUMLIN Y, HOF RP: Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice. Transplantation (2003) 76:1166-1170.
   PubMed Web of Science ®Google Scholar
• GRUBE E, SONODA S, IKENO F et al.: Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation (2004) 109:2168-2171.
   PubMed Web of Science ®Google Scholar
• KIRCHNER GI, MEIER-WIEDENBACH I, MANNS MP: Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. (2004) 43:83-95.
   PubMed Web of Science ®Google Scholar
• KOVARIK JM, KAPLAN B, SILVA HT et al.: Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. Am. J. Transplant (2003) 3:606-613.
   PubMed Web of Science ®Google Scholar
• NASHAN B: Review of the proliferation inhibitor everolimus. Expert Opin. Investig. Drugs (2002) 11:1845-1857.
   PubMed Web of Science ®Google Scholar
• CURTIS J, NASHAN B, PONTICELLI C: A multicenter, randomized, open-label, parallel-group study of the efficacy and safety of everolimus (RAD) given with basiliximab, corticosteroids, and either full- or reduced-dose CsA in de novo renal transplant recipients. Am. J. Transplant. (2001) 1(Suppl. 1):474.
   Google Scholar
• LORBER MI, MULGAONKAR S, BUTT KM et al.: Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, Phase III study. Transplantation (2005) 80:244-252.
   PubMed Web of Science ®Google Scholar
• KOVARIK JM, KAPLAN B, TEDESCO SILVA H et al.: Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. Transplantation (2002) 73:920-925.
   PubMed Web of Science ®Google Scholar
• LORBER MI, PONTICELLI C, WHELCHEL J et al.: Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin. Transplant. (2005) 19:145-152.
   PubMed Web of Science ®Google Scholar
• VITKO S, MARGREITER R, WEIMAR W et al.: Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation (2004) 78:1532-1540.
   PubMed Web of Science ®Google Scholar
• OPPENHEIMER F, OYEN O, VILJOEN H, VITKO S: 36-month results of an international study with everolimus for the prevention of allograft rejection in de novo kidney transplant recipients. Presented at The Fourth Joint American Transplant Meeting. Washington (DC) USA(2003).
   Google Scholar
• NASHAN B, CURTIS J, PONTICELLI C, MOURAD G, JAFFE J, HAAS T: Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year Phase II, randomized, multicenter, open-label study. Transplantation (2004) 78:1332-1340.
   PubMed Web of Science ®Google Scholar
• VITKO S, TEDESCO H, ERIS J et al.: Everolimus with optimized cyclosporine dosing in renal transplant recipients:6-month safety and efficacy results of two randomized studies. Am. J. Transplant. (2004) 4:626-635.
   PubMed Web of Science ®Google Scholar
• KOBASHIGAWA JA, TOBIS JM, STARLING RC et al.: Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J. Am. Coll. Cardiol. (2005) 45:1532-1537.
   PubMed Web of Science ®Google Scholar
• TUZCU EM, KAPADIA SR, SACHAR R et al.: Intravascular ultrasound evidence of angiographically silent progression in coronary atherosclerosis predicts long-term morbidity and mortality after cardiac transplantation. J. Am. Coll. Cardiol. (2005) 45:1538-1542.
   PubMed Web of Science ®Google Scholar
• MANCINI D, VIGANO M, PULPON L: 24-Month results of a multicenter study of Certican for the prevention of allograft rejection and vasculopathy in de novo cardiac transplant recipients. Am. J. Transplant. (2003) 3:550.
   Google Scholar
• AVERY RK: Viral triggers of cardiac-allograft dysfunction. N. Engl. J. Med. (2001) 344:1545-1547.
   Google Scholar
• TAYLOR DO, EDWARDS LB, MOHACSI PJ et al.: The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report-2003. J. Heart Lung Transplant. (2003) 22:616-624.
   PubMedGoogle Scholar
• VALENTINE V, LOVE R, SNELL G, VITULO P, GLANVILLE A, PIRRON U: Everolimus (RAD) shows superiority over azathioprine to inhibit the decline of pulmonary function in stable lung transplant recipients: 24 month results of a multicenter, randomized double-blind study. Am. J. Transplant. (2004) 4(Suppl. 8):269.
   Google Scholar
• KING-BIGGS MB, DUNITZ JM, PARK SJ, KAY SAVIK S, HERTZ MI: Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation. Transplantation (2003) 75:1437-1443.
   PubMed Web of Science ®Google Scholar
• DUTLY AE, GASPERT A, INCI I, SCHNEITER D, KOROM S, WEDER W: The influence of the rapamycin-derivate SDZ RAD on the healing of airway anastomoses. Eur. J. Cardiothorac. Surg. (2003) 24:154-158; discussion 158.
   PubMed Web of Science ®Google Scholar
• KUPPAHALLY S, AL-KHALDI A, WEISSHAAR D et al.: Wound healing complications with de novo sirolimus versus mycophenolate mofetil-based regimen in cardiac transplant recipients. Am. J. Transplant. (2006) 6:986-992.
   PubMed Web of Science ®Google Scholar
• CHAN S: Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer (2004) 91:1420-1424.
   PubMed Web of Science ®Google Scholar
• VIGNOT S, FAIVRE S, AGUIRRE D, RAYMOND E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. (2005) 16:525-537.
   PubMed Web of Science ®Google Scholar
• BOULAY A, ZUMSTEIN-MECKER S, STEPHAN C et al.: Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. (2004) 64:252-261.
   PubMed Web of Science ®Google Scholar
• LANE H, SCHNELL C, THEUER A: Antiangiogenetic activity of RAD 001, an orally active anticancer agent. Proc. Am. Assoc. Cancer Res. (2002) 43:Abstr. 922.
   Google Scholar
• SHINOHARA ET, CAO C, NIERMANN K et al.: Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene (2005) 24(35):5414-5422.
   PubMed Web of Science ®Google Scholar
• BEUVINK I, BOULAY A, FUMAGALLI S et al.: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell (2005) 120:747-759.
   PubMed Web of Science ®Google Scholar
• MAJEWSKI M, KORECKA M, JOERGENSEN J et al.: Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation (2003) 75:1710-1717.
   PubMed Web of Science ®Google Scholar
• MAJEWSKI M, KORECKA M, KOSSEV P et al.: The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc. Natl. Acad. Sci. USA (2000) 97:4285-4290.
   PubMed Web of Science ®Google Scholar
• STALLONE G, SCHENA A, INFANTE B et al.: Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N. Engl. J. Med. (2005) 352:1317-1323.
   PubMed Web of Science ®Google Scholar
• HOLMES M, CHILCOTT J, WALTERS S, WHITBY S, AKEHURST R: Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients. Transpl. Int. (2004) 17:182-187.
   Google Scholar
• RADEVA JI, REED SD, KALO Z et al.: Economic evaluation of everolimus versus azathioprine at one year after de novo heart transplantation. Clin. Transplant. (2005) 19:122-129.
   Google Scholar
• EISEN HJ, STARLING RC, YANG L, AL E: 4-year incidence of MACE and economic burden in de novo heart transplant patients; a comparison of everolimus and azathioprine. Am. J. Transplant. (2005) 5:251. Abstract.
   Google Scholar